A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole.

Trial Profile

A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole.

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2013

At a glance

  • Drugs Iloperidone (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms i-FANS
  • Sponsors Novartis
  • Most Recent Events

    • 09 May 2012 Trial design presented at the 165th Annual Meeting of the American Psychiatric Association.
    • 01 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Oct 2011 Planned end date changed from 1 Dec 2012 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top